Jennifer Good is our co-founder, President and Chief Executive Officer since our inception in March 2011 and has built the company from its initial seed funding through being a nasdaq-traded company. Previously, Ms. Good served at Penwest Pharmaceuticals Co. from 1997 to 2010, where she held various executive positions including serving as its President and Chief Executive Officer the final years before the company was acquired by its strategic partner. Ms. Good also currently serves on the board of Rhythm Pharmaceuticals, a publicly traded biopharmaceutical company, and is a member of Rhythm's Audit Committee. Previously, Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. Ms. Good also serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia and is on the Board of Bio, a biotech advocacy group. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.